Composition for treatment or prevention of gastrointestinal infection

FIELD: medicine.

SUBSTANCE: composition for treatment and/or prevention of infection with gastrointestinal pathogens and/or disease of mammals, associated with infection by said pathogens, contains lipid, protein and hydrocarbon part, where lipid part provides from 5 to 50% of total number of calories, protein part provides from 5 to 50% of total number of calories and carbohydrate part provided from 15 to 90% of total number of calories. Protein part contains: (i) pea protein hydrolysate and (ii) at least one source of nitrogen, selected from the group, consisting of milk proteins, milk protein hydrolysate, egg protein and egg protein hydrolysate.

EFFECT: application of claimed composition in mixture composition makes it possible to increase efficiency of treatment or prevention of infection with gastrointestinal pathogens, in particular, Helicobacter pylori, or disease of mammals, associated with said pathogen infection.

1 ex, 1 tbl

 

The technical FIELD TO WHICH the INVENTION RELATES.

The present invention relates to the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori.

The prior art INVENTIONS

Gastrointestinal infection is an acute problem for many people, in particular children and patients with a weakened immune system or gastrointestinal diseases. Diseases that result, can be life-threatening. Cause of gastrointestinal infections often Escherichia coli, Salmonella, Campylobacter, Clostridium, Enterobacter, and Helicobacter, such as Helicobacter pylori.

Helicobacter pylori (H. pylori) is a gram-negative microaerophilic flagellate bacterium, which is when the infection gets into the lining of the human stomach. Infection with H. pylori is associated with severe diseases of the stomach, such as gastritis, stomach ulcers and stomach cancer. The world Health Organization has classified H. Pylon as a carcinogen Group I. Usually the H. pylori infection is chronic and cannot be cured without special treatment.

Infection with H. pylori infection usually occurs in early childhood. Most children are infected during the first 5 years of life [Vandenplas Y, Curr Opin Infect Dis 2001; 14(3): 315-321]. To 10 years, the overall prevalence of infection is more than 75% in developing countries, whereas in developed countries are infected and are 10%, but in children of lower socio-economic groups, the prevalence may be as high as 30-40%.

The transfer mechanism of H. pylori is still not completely understood and requires further research. There are oral-oral, gastro-oral (through vomiting), fecal-oral route, drinking tap water (in developing countries), or even poorly cleaned endoscopic equipment.

For treatment of the infection N. pylori requires from three to four drugs. Canadian and most European groups of researchers N. pylori is now recommended (for adults) triple mode: twice a day proton pump inhibitor in combination with two antibiotics, for example clarithromycin and amoxicillin in 1-2 weeks. The treatment is quite expensive, in addition, there is the risk of increasing resistance of bacterial strains to antibiotics and the risk of re-infection after treatment has failed. Treatment of children is probably the most cost-effective method of reducing the prevalence and morbidity and mortality from diseases associated with H. pylori. To date, there is not a methodical recommendations about the need for treatment of children. Vaccine for humans is not yet available. Prophylactic and therapeutic vaccination has been successful in animal models, noperiod in the vaccine for human remains complex, partly because of the fact that immunology stomach is still poorly understood.

Taking into account the problems with antibiotic treatment and prophylaxis by vaccination, it is necessary to prevent the adhesion of H. pylori to the gastric mucosa. Without the adhesion of the bacteria risk associated inflammation, leading to gastritis or perhaps to cancer, can be minimized. Modulation of the diet (probiotics) have proven useful in maintenance therapy when infection N. pylori, or the prevention of in vivo and in vitro [Michetti P, et al. Digestion 1999; 60(3): 203-209 and Midolo PD, et al., J Appl Bacteriol 1995; 79(4): 475-479].

WO 94/18986 refers to the use of di - or oligosaccharide glycosides containing at least one terminal unit L-fucose for the preparation of pharmaceutical compositions for treatment or prevention in people conditions that lead to infection of H. pylori in the gastric mucosa of man.

EP 0713700 describes a method of inhibiting Helicobacter by receiving C8-C16 of monoglycerides of fatty acids or lauric acid. Monoglycerides and/or lauric acid just take as a nutritional composition.

EP 1178104 relates to a nutritional composition that contains specific essential oil and/or special cleaned component of essential oils for the prevention or treatment of infection of Helicobacter - like organism. The nutritional composition may also content is th source of hydrocarbons, the source of fat and/or source of dietary protein peas as one of them.

JP 2005255679 describes the polypeptide obtained by processing the buttermilk protease possessing not only inhibitory effect on the adhesion of Helicobacter pylori to the gastric mucosa, but also the effect of the buoyancy of Helicobacter pylori from gastric mucosa carriers of Helicobacter pylori.

JP 2001335504 describes inhibitor of proliferation of Helicobacter pylori, as active ingredient containing enzyme hydrolyzed soy protein.

DE 10317935 describes the use of casein for the preparation of compositions for preventing or treating Helicobacter infection and for prevention of diseases associated with Helicobacter infection.

The INVENTION

The present invention relates to the use of a composition containing hydrolyzed pea protein, intact pea protein and/or protein hydrolysate camel milk for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals associated with infection of these pathogens, particularly infections of the gastro-intestinal pathogen selected from the group consisting of Helicobacter, Escherichia coli, Salmonella, Campylobacter, Clostridium and Enterobacter. Moreover, the invention relates to the use of hydrolyzed pea protein, intact pea protein and/or protein hydrolysate camel milk for Prigat the effect of the composition for treatment and/or prevention of infection or disease, accordingly, the above.

The authors of the present invention have found that hydrolyzed pea protein, intact pea protein and hydrolyzed camel casein (hereinafter jointly referred to as "the present protein component) is able to inhibit the adhesion of N. pylori cells of the gastric mucosa. Terms hydrolyzed pea protein and hydrolyzed camel casein (hereinafter jointly referred to as "the present protein hydrolysate component") in the form in which they are used in the text, refer to peptides and/or glycoconjugates, but preferred are peptides obtained by hydrolysis of pea protein and/or obtained by the hydrolysis of camel casein. Inhibition of adhesion makes these protein components are particularly suitable for use in the method of treatment and/or prevention of Helicobacter infection.

Especially good results were obtained with the pea protein hydrolysates. Preferably hydrolyzed pea protein was obtained from protein extracts of pea. Protein extracts from pea preferably contains at least 75 mass % pea protein per 100 grams of isolate protein peas.

This protein component and, in particular, the hydrolysate of the present protein component can be easily added to children's milk compositions, products for kids and food for the undergrowth is impressive. Simplicity and security in the use of this protein component attaches particular importance to this invention, since it solves the problems of side effects commonly associated with medication and expensive multilocational therapy. This protein component can also easily take the adults.

An additional advantage of using the present protein component, in particular, the present protein hydrolysate of pea is that it is preferable and usually dissolves quickly in water, for example, making it particularly suitable for use as a liquid food product. This gives the advantage that a real anti-infective protein component is not necessary to provide separately (for example, children), and you can take in the nutrient composition.

Due to the fact that increased duration of breastfeeding in infancy may have long-term protective effect against chronic infection N. pylori and thus reduce the risk of gastric carcinoma (|J Pediatr Gastoenterol Nutr. 2005 Nov; 41(5): 617-20), is particularly desirable to protect against infection by N. pylori in children who receive child milk composition. Unexpectedly, it was found that this protein component (in particular hydrolyzed pea protein) can be used to reduce and/or prevent infection N. pylori.

In the following embodiment of the present protein component can be used to prevent infections of the gastro-intestinal pathogens to prevent re-infection of the gastro-intestinal pathogen after antibiotic treatment, in particular the prevention of infection N. pylori to prevent re-infection N. pylori after treatment with antibiotics.

As described, the H. pylori infection in early life increases the risk of intestinal cancer, particularly gastric carcinoma, gastritis and stomach ulcers, the present invention also provides a method of preventing these diseases by taking hydrolyzed pea protein and/or protein hydrolysate camel milk.

A DETAILED DESCRIPTION of the PREFERRED EMBODIMENTS

The present invention relates to the use of a composition containing hydrolyzed pea protein, intact pea protein and/or protein hydrolysate camel milk for the preparation of compositions for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection specified gastrointestinal pathogens.

The present invention also provides a method for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection of the gastro-intestinal Pat the genes, the method includes receiving these mammals hydrolyzed pea protein, intact pea protein and/or protein hydrolysate camel milk. Preferably the mammal is a baby or child, more preferably a child aged 0 to 5 years and/or a patient suffering from diseases of the stomach and duodenum.

In the following aspect the present invention provides a composition comprising a lipid portion, providing from 5 to 50% of the total calories, the protein of providing from 5 to 50% of your total calories, and the hydrocarbon portion that provides 15 to 90% of your total calories. This composition is characterized by the fact that the protein portion includes: (i) at least one protein source selected from the group consisting of hydrolyzed pea protein, intact pea protein and protein hydrolysate camel milk; and (ii) at least one nitrogen source selected from the group of milk proteins, hydrolyzed milk protein, egg protein, hydrolyzed egg protein, soy protein, hydrolyzed soy protein, wheat protein, hydrolyzed wheat protein, rice protein, hydrolyzed rice protein, free amino acids and mixtures thereof. As used above, the terms "lipid part, the protein portion and a hydrocarbon portion" means the sum of all lipid in which Reventon, protein ingredients or hydrocarbon ingredient, respectively, present in the composition.

In the same aspect the present invention includes the use of this composition for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection specified gastrointestinal pathogen.

The next subject of the present invention is hydrolyzed pea protein, intact pea protein and/or protein hydrolysate camel milk for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection specified gastrointestinal pathogen.

Protein

The present invention provides a composition comprising a hydrolyzed pea protein, intact pea protein and/or protein hydrolysate camel's milk, and the use of this composition for this therapy.

It was found that the hydrolysate camel casein is also extremely effective. Thus, in one embodiment of the present invention preferably contains hydrolyzed protein camel milk, preferably hydrolyzed camel casein.

Preferred real hydrolyzed protein component is hydrolyzed pea protein.

Certain methods gel electrophoresis (LDS-P is AG with Coomassie blue staining and silver) and mass spectrometry MALDI, the range of molecular weights is the most effective anti-adhesive to Helicobacter peptides and/or glycoconjugates in the present protein hydrolysate component is 300-12000 Yes, preferably 2200-6000 Yes. Thus, the present protein hydrolysate component preferably contains at least 1 mass % of the peptides and/or glycoconjugates (preferably peptides) with a molecular weight of from 300 to 12,000 Da relative to the total weight of this protein hydrolysate, preferably at least 5 mass %, more preferably at least 50 mass %, most preferably at least 75 mass %. More preferably, the present protein hydrolysate component contains at least 1 mass % of the peptides and/or glycoconjugates (preferably peptides) with a molecular weight of from 2200 to 6600 Yes relative to the total weight of this protein hydrolysate, preferably at least 5 mass %, more preferably at least 50 mass %, most preferably at least 75 mass %.

This protein component and, in particular, the present protein hydrolysate component preferably take in the amount of from 0.1 to 100 grams per day, preferably in quantities of from 0.5 to 10 grams per day.

Gastrointestinal pathogens

The present method relates to the treatment of the/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection specified gastrointestinal pathogen, in particular the treatment and/or prevention of infection by gastrointestinal pathogen selected from the group consisting of Helicobacter, Escherichia coli, Salmonella, Campylobacter, Clostridium and Enterobacter and/or diseases of mammals, associated with infection specified gastrointestinal pathogen.

The present invention particularly provides for the treatment and/or prevention of Helicobacter infections and/or diseases of mammals, associated with Helicobacter infection. Helicobacter preferably selected from the group consisting of Helicobacter pylori, Helicobacter bizzozeronii, H. salomonis, Helicobacter heilmannii and Helicobacter felis. Preferably the present invention provides treatment and/or prevention of infection with Helicobacter pylori (H. pylori) and or diseases of mammals, associated with Helicobacter pylori infection.

Food composition

It was found that this protein component and, in particular, the hydrolysate of the present protein component can be added to food such as baby food and clinical nutrition, in particular baby food. The present nutritional composition mainly contains the lipid part of the protein portion and a hydrocarbon portion.

Thus, the present invention also relates to a nutritional composition containing the present protein component and preferably a hydrolysate of the extract is its protein component and their use in the present method, where the lipid part provides 5 to 50% of the total calories, the protein of provides from 5 to 50% of your total calories and hydrocarbon part provides 15 to 90% of your total calories. This composition is preferably used as infant formula, where the lipid part provides 35 to 50% of the total calories, the protein of provides from 7.5 to 12.5% of the total number of calories and hydrocarbon part provides from 40 to 55% of total calories. To calculate the % of your total calories for the protein part you must consider all the proteins, peptides and amino acids.

In addition to this hydrolyzed pea protein, intact pea protein and/or a hydrolysate of camel casein present composition for increasing the nutritional value preferably contains an additional nitrogen source. An additional source of nitrogen is preferably selected from the group consisting of protein, peptide, amino acids and their compositions. Thus, in a preferred execution of the protein of the present composition contains: (i) at least one protein source selected from the group consisting of hydrolyzed pea protein, intact pea protein and protein hydrolysate camel milk; and (ii) at least one nitrogen source selected from the group of milk proteins, Yai is different proteins, soy protein, wheat protein, rice protein, free amino acids and mixtures thereof. Preferably the present invention contains (i) hydrolyzed pea protein and (ii) at least one nitrogen source selected from the group hydrolyzed bovine serum, non-hydrolyzed cow's whey, hydrolyzed cow's casein, non-hydrolyzed cow's casein and non-hydrolyzed soy protein.

When the present protein component and, in particular, the hydrolysate of the present protein component is taken in combination with an additional source of nitrogen, the present composition preferably contains from 1 to 50 mass % of the present protein component and in particular of the hydrolyzate of the present protein component relative to the total weight of a protein.

In the nutritional composition may be an added source of easily digestible carbohydrates. The present composition preferably contains lactose.

In the preferred embodiment of the anti-infective effect of this protein component and in particular of the hydrolyzate of the present protein component, preferably the protein hydrolysate of pea against gastrointestinal pathogens is enhanced by the simultaneous adoption of a soluble, hard to digest, fermentive oligosaccharide. The reception of these oligosaccharides stimulate the growth of lactoba the bacilli, such as bifidobacteria and lactobacilli, which prevents the penetration and infection by gastrointestinal pathogens. Thus, the present protein component (hydrolysate) and real oligosaccharide act synergistically. This oligosaccharide is preferably selected from the group consisting of galactooligosaccharides and fructo-oligosaccharides (e.g., inulin). Preferably at least 50 mass % of these oligosaccharides have a degree of polymerization of from 2 to 60. In a particularly preferred embodiment the present composition comprises at least galactooligosaccharide and fructo-oligosaccharides. Galactooligosaccharide preferably contain saccharides with a degree of polymerization of from 2 to 10. Fructo-oligosaccharides preferably contain saccharides with a degree of polymerization of from 2 to 60.

The irregularity of the chair (for example, constipation, insufficient stool or diarrhea) is a specific problem for many children and patients who have an infection or risk of infection N. pylori. These patients often receive liquid food. It was found that the stool can be reduced by taking this protein component in the composition of the liquid food with osmotic solution concentration from 50 to 500 mOsm/kg, more preferably from 100 to 400 mOsm/kg Preventing problems with a chair has osobowego, when the present protein component is taken together with or after antibiotic treatment. Given the above, it is also important that the liquid food was not very nutritious, but put enough calories to satisfy the patient. Thus, the liquid food preferably has a caloric content of from 0.1 to 2.5 kcal/ml, even more preferably, the caloric content of from 0.5 to 1.5 kcal/ml, most preferably from 0.6 to 0.8 kcal/ml

Application

The present invention provides a composition and method for treatment and/or prevention of infection by gastrointestinal pathogens (in particular N. pylori) and/or human disease associated with infection by gastrointestinal pathogens (in particular N. pylori), the method includes receiving a man of the present protein component and in particular of the hydrolyzate of the present protein component. Diseases associated with infection by gastrointestinal pathogens include permanent chronic gastritis, diarrhea, abdominal pain, ulcers, and/or stomach cancer. Human diseases associated with H. pylori infection include permanent chronic gastritis, ulcers, and/or stomach cancer. The present invention also provides for the treatment and/or prevention of these diseases at risk or in need of treatment.

The present image is eenie refers to the treatment and prevention of diseases of a mammal, preferably human or animal, more preferably a human. This composition can easily take a) children aged 0 to 5 years, preferably children aged 0 to 2 years and/or b) patients suffering from diseases of the stomach and duodenum, especially patients suffering from stomach ulcers.

The present invention is also particularly suitable to prevent re-infection by gastrointestinal pathogens, in particular N. pylori after treatment of a mammal one or more antibiotics.

EXAMPLES

Example 1: anti-infective effect of the hydrolyzate of the present protein component

I. Receiving antiadhesive peptides and glycoconjugates by enzymatic hydrolysis

Protein peas: protein extracts from pea (90% protein) was dispersible in distilled water to a concentration of 2.5 wt./wt.%. The hydrolysis 180 min at 50°C by the addition of trypsin and chymotrypsin in the ratio of enzyme: substrate = 1:150 by weight for each protease. By adding sodium hydroxide during hydrolysis maintained a constant pH level 7,80. Enzymes iactiveaware by heating to 85°C. and maintaining the temperature from 85 to 80°C for 5 minutes. The suspension was rapidly cooled on ice to room temperature, then centrifuged at 3800 g for 15 minutes at 20°C. the su is inatant were selected and subjected to freeze drying.

Camel casein: camel casein (85% protein) was dissolved in distilled water to a concentration of 5 wt./wt.%. The hydrolysis 120 min at 37°C by adding TRNC treated with trypsin ratio of enzyme: substrate = 1:89 mass. By adding sodium hydroxide during hydrolysis maintained a constant pH level 7,00. The hydrolysis was stopped by adding hydrochloric acid to pH 4,60, and the insoluble part was removed by centrifugation at 3100 g for 20 minutes at 4°C. the Supernatant was collected, brought to neutral pH of 6.90 and subjected to freeze drying.

II. Purification of peptides and glycoconjugates by ultrafiltration (peptides and glycoconjugates from protein extracts of pea)

Hydrolyzed pea protein was dissolved in distilled water to a concentration of 1 wt./vol.%. Ultrafiltration was carried out on a centrifugal filter Amicon® Ultra-15 or Method® Plus-20 (Millipore GmbH, Schwalbach, Germany). Device to obtain a release to H. pylori fractions have a nominal cut-off molecular weight (NMWCO) 10 kDa for Amicon® Ultra-15 or 5 kDa for Method® Plus-20. To remove a humectant (glycerol) pre-filters were washed with distilled water by centrifugation for 5 minutes at 4500 rpm (4000 g) at 10°C (centrifuge Beckman J2-21, rotor JS to 7.5). This step was repeated once. The sample was centrifuged at 4500 rpm (4000 g) in t is within 30 min at 10°C. The filtrate was collected and the filter cake was diluted to approximately its original volume and repeated centrifugation. This step was repeated again, and the filter cake was again diluted to its original volume. Then the filter cake was collected. The filtrate and the filter cake was subjected to freeze drying.

III. In situ test for adhesiveness to N. pylori

Test in situ was mainly carried out by the method of Falk et al. (Falk et al., Proc. Natl. Acad. Sci. 1993; 90:2035-2039). Used bacterial strain G27 N. pylori type I. For the analysis of anti-adhesive activity of peptides and glycoconjugates, aliquots (100-200 µl) FITC labeled N. pylori 2 hours in the dark was preincubated with samples of peptides and glycoconjugates (0,01-0,1% in blocking buffer). The control were labeled with FITC, but not processed, i.e. without addition of peptides and glycoconjugates, aliquots N. pylori. Labeled FITC bacterial suspension was diluted blocking buffer 20 times and 200 μl, respectively, were placed on a glass slide with a slice of the mucosa of the human stomach, and incubated. After washing with fluorescent microscopy watched the adhesion of bacteria. Comparable results were obtained by incubation of the slice of the gastric mucosa with peptides and glycoconjugates instead incubation with them N. pylori.

IV. Results

Hydrolysates of human casein, camel casein and especially Belk the peas inhibit the adhesion of H. pylori to the gastric mucosa compared with control (untreated H. pylori). When using the peptides of casein of human milk adhesion can be reduced by more than 60%, when using peptides camel casein approximately 80%, and the use of peptides, proteins and glycoconjugates peas even 95% in comparison with the control group (see Table 1). These results reflect the benefits of using hydrolyzed pea protein and/or a hydrolysate of camel casein in the treatment and/or prevention of H. pylori infections and/or diseases of mammals, associated with H. pylori infection.

TABLE 1
IngredientAdhesion of H. pylori (%)
Control100
Hydrolyzed proteins bovine serum100
Hydrolyzed bovine casein100
Hydrolyzed human casein34
Hydrolyzed camel casein21
Hydrolyzed protein pea 5

1. The use of a composition containing hydrolyzed pea protein, for the preparation of compositions for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection specified gastrointestinal pathogen, through the introduction of mammals.

2. The use according to claim 1, where the pathogen is Helicobacter.

3. The use according to claim 2, where the pathogen is Helicobacter pylori (H. pylori).

4. The use according to any one of the preceding paragraphs, where the disease associated with the infection, which are selected from the group consisting of gastritis, stomach ulcers and stomach cancer.

5. The use according to any one of the preceding paragraphs, where the mammal is (i) a child aged 0 to 5 years, or (ii) a patient suffering from diseases of the stomach and duodenum.

6. The use according to any one of the preceding paragraphs to prevent re-infection by the pathogen after treatment of a mammal one or more antibiotics.

7. Composition for treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals associated with infection of these pathogens containing lipid, protein and carbohydrate part, where the lipid part provides 5 to 50% of the total calories, the protein of provides from 5 to 50% of the total to which icesta calories and carbohydrate part provides 15 to 90% of the total number of calories wherein the protein portion includes: (i) hydrolyzed pea protein, and (ii) at least one nitrogen source selected from the group consisting of milk proteins, hydrolyzed milk protein, egg protein and egg protein hydrolysate.

8. The composition according to claim 7, where the nitrogen source is selected from the group consisting of hydrolyzed bovine serum, non-hydrolyzed cow's whey, hydrolyzed cow's casein and non-hydrolyzed cow's casein.

9. Composition according to claims 7 and 8, containing soluble hard to digest fermentary oligosaccharide.

10. Composition according to any one of claims 7 to 9, with osmollnosti solution from 50 to 500 mOsm/kg

11. The use of a composition according to any one of claims 7 to 10 for the preparation of a mixture for the treatment and/or prevention of infection with Helicobacter pylori (H. pylori) and/or diseases of mammals, associated with Helicobacter pylori infection.

12. Hydrolyzed pea protein for the treatment and/or prevention of infection by gastrointestinal pathogens and/or diseases of mammals, associated with infection specified gastrointestinal pathogen.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry and specifically to novel biologically active indazole compounds: 3-(2-bromophenyl)-4,5,6,7-tetrahydroindazole hydrochloride (1a) and 3-benzyl-4,5,6,7-tetrahydroindazole hydrochloride (1b) of general formula: Ia, b (R=C6H4Br-2 (a), CH2C6H5 (b)). The invention also relates to an antimicrobial agent based on compounds of formula (1a) or (1b).

EFFECT: novel indazole derivatives having antibacterial activity are obtained.

2 cl, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, in particular, to production of drugs for external application. As shaping component used is sterile hydrophilic powder of Kimmeridgian (blue) medicinal "Undorovskaya" powder-like, as deodorating -menthol powder, and as solvent and penetrator - dimethylsulphoxide with the following ratio of components (wt %): menthol 1.5-3.5, furacillin 1.0-5.0, dimethylsulphoxide 20.0-24.0, blue clay 74.0-67.0.

EFFECT: invention ensures increase of therapeutic efficiency in wound treatment, possessing adsorption, antimicrobial and deodorating action.

3 tbl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to obtaining and application of staphylococcal anatoxin-vaccine for prevention and treatment of animal diseases of staphylococcal etiology. Method by invention includes growing staphylococci on synthetic nutritional medium with further autoclaving of obtained suspension of microorganisms. After that, detoxication of obtained complex of staphylococcal exo-, endo- and superenterotoxins is performed by two detoxicators: first by 0.2-0.3% glutardehyde solution during 3-5 days at 40-42°C, then by 0.2% ethonium solution or 0.15-0.25% solution of alkylmethylbenzyl ammonium during 3-5 days at 40-42°C. After that, target product is sorbed on aluminium hydroxide in dose 3-5 mg/ml.

EFFECT: method application makes it possible to increase protective and therapeutic efficiency and safety of anatoxin-vaccine.

1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to peptides having antibacterial and endotoxin-neutralising activity, having general formula (Xaa1)M-(Xaa2)o-Xaa3-(Xaa4)p-(Xaa5)Q-(Xaa6)M-(Xaa7)R-(Xaa8)S.

EFFECT: obtaining peptides with antibacterial and endotoxin-neutralising activity.

43 cl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes genetically modified Shigella bacteria, which have deletions or gene modifications: virG(icsA) in combination with two or more genes setAB(shET 1), senA(shET2), senB(shET2- 2), stxAB and msbB2. Obtained bacteria have three or more deletions in identified genes and can be used as vaccine strains against dysentery and diarrhea, caused by Shigella. Constructed are the following specific vaccine strains: WRSS3 (ΔsenA, ΔsenB, ΔvirG, ΔmsbB2), WRSf2G15 (ΔvirG, ΔsetAB, ΔsenA, ΔsenB, ΔmsbB2) and WRSd5 (ΔvirG, ΔstxAB, ΔsenA, ΔsenB, ΔmsbB2), on the basis of which created are immunogenic compositions, live and invasive vaccines and sets, aimed at prevention and treatment of said diseases.

EFFECT: vaccine strain by invention is safer and when used will attenuate or eliminate symptoms of high temperature and diarrhea in people.

14 cl, 12 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: during phases of regeneration and epithelisation, a wound surface is coated with a dressing impregnated with an ointment of the following composition, wt %: organic-silicon glycerohyrogel - 95.25, ciprofloxacin - 0.2, oxytocin - 4.55.

EFFECT: method provides faster regenerative processes at the II and III phases of the wound process, prevented the onset of persistent infection and purulent-septic complications, reduced length of treatment.

2 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gynecology. Simultaneously with intravenous introduction of antibacterial preparations performed is ultrasound low-frequency impact dynamically distributed on external surface of uterus area. Impact is performed with the following parameters: frequency 34-46 kHz and amplitude 4-12 mcm. Rate of dynamic distribution of impact is directly proportional to its amplitude.

EFFECT: method contributes to normal course of puerperium, prevention of local infectious complications.

2 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: there are presented versions of recombinant virulent polypeptides and nucleic molecules coding them with the sequences disclosed in the description, used to prepare a vaccine composition for A/E-pathogen. What is described is a vaccine composition for inducing a response on A/E-pathogen in animals containing said nucleic acid molecule; a cell culture supernatant containing said polypeptide; and/or a bacterium or its preparation having a mutation in its genome in said nucleic acid molecule inducing virulence attenuation, or having nleA gene deletion in a combination with a physiologically acceptable carrier. What is presented is a method for virulence attenuation of A/E-pathogen, involving nleA gene deletion in A/E-pathogen or deletion of one or more said nucleic acids in the A/E-pathogen genome.

EFFECT: invention provides producing the effective vaccine.

24 cl, 2 tbl, 27 dwg, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel heterocyclic radicals of formulae and , having bactericidal and fungicidal properties, which can be used in veterinary and medicine, as well as labels when investigating metabolic routes of medications in living organisms.

EFFECT: novel, unparalleled bactericidal and fungicidal compounds are disclosed.

1 cl, 1 tbl, 3 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: invention is applicable in veterinary science for treating mastitis in animals. A tylosin agent for treating mastitis in animals additionally contains glycerol, Carbopol, triethanol amine, fir essence in the following proportions, %: tylosin 0.05-1.0; glycerol 5.0-10.0; Carbopol 0.15 -0.20; triethanol amine 0.02-0.03; fir essence 0.1-0.3; water up to 100. The agent shows a good wound healing effect, creates a thin surface film, soothes skin, possess antiseptic properties, ability to scare insects, flies in particular.

EFFECT: invention provides higher preventive effectiveness of the agent and lower cost price of animal treatment.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for prevention or treatment of inflammatory intestinal diseases (IID), which contains 7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triasolo[4,5-c][1]-benzazepine, or its prodrug, preferably 2-(1-isopropoxycarbonyloxy-2-methypropyl)-7,8-dimethoxy-4(5H), 10-dioxi-2H-1,2,3-triasolo[4,5-c] [1]benzazepine, or its pharmaceutically acceptable salt; respective method of prevention or IID treatment and application of said compounds for manufacturing preventive or therapeutic substance against IID. Demonstrated is efficiency of claimed pharmaceutical composition, more powerful than sulfasalazine and prednisolon with respect to said purpose, in combination with high safety. Shown are few side effects of compounds, absence of inhibition of IL-2, IL-4, IL-5, IFN-gamma, absence of weight gain restraint resulting from treatment.

EFFECT: pharmaceutical composition in accordance with claimed invention can demonstrate powerful preventive and therapeutic action, even in case of severe form of disease with resistance to conventional therapeutic agents.

28 cl, 3 dwg, 9 tbl

FIELD: medicine.

SUBSTANCE: composition contains at least one triglyceride, acyl group consisting of residues of saturated, monounsaturated and polyunsaturated fatty acids with the total contents of palmitoleic acid residues in the composition making approximately 15-55% of the total content of fatty acid residues. At least 13% of the total content of fatty acids in a position of sn-2 carbon skeleton of triglyceride represent palmitoleic acid residues in the composition. What is presented is a method of treating and preventing a condition in a subject suffering or having a severe risk to suffer short bowel syndrome, intestinal inflammatory disease or necrotising enterocolitis, and activation of intestinal development, maturation, adaptation and differentiation involving the introduction of said lipid composition into a subject.

EFFECT: invention enables preventing or avoiding said intestinal disorders in a subject.

37 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of combination of (a) 13,14-dihydro-15-keta-16,16-dihalogen-derivative of prostaglandin, represented by formula (II) and (b) inhibitor of H+, K+-ATPase, which represents compound of general formula (II) in combination with pharmaceutically acceptable excipient for manufacturing pharmaceutical composition (demonstrating synergistic effect in treatment of gastrointestinal disorders), for treatment of gastrointestinal diseases and corresponding treatment method and synergistic pharmaceutical composition of the same purpose.

EFFECT: demonstrated is synergism of combination of 13,14-dihydro-15-keto-16,16-difluoroprostaglandin E1 in combination with omeprazole or lansoprazole in reduction of gastric ulcer dimensions.

15 cl, 1 dwg, 5 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used for treatment of precancerous and early cancerous diseases of stomach. Step-by-step combined treatment is carried out. Pylobact, which includes two antibiotics: clarithromycin 500 mg and thinidasole 500 mg, and omeprazole 20 mg or combination of amoxicillin 500 mg units and metronidazole 250 mg are administered in accordance with the scheme. Simultaneously infusion of the herb "Wartwort" and tincture of the herb "Callisia fragrans" are administered in accordance with the scheme. In case of duodenogastric reflux anti-reflux medications are administered. After application of medications control test aimed at determination of quantitative change of microorganisms (Hp) in gastric mucosa is performed and on the basis of its results necessity of repeated scheme of treatment is determined.

EFFECT: method makes it possible to carry out Hp eradication and reduce damaging action of bile on gastric mucosa.

5 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to crystalline forms A, B and F of racemic ilaprazole (2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]thionyl]-5-(1H-pyrrol-1-yl)-1H-benzimidazole). The invention also relates to a pharmaceutical composition based on crystalline ilaprazole and use of crystalline ilaprazole.

EFFECT: obtaining novel crystalline forms of ilaprazole which can be used to inhibit gastric acid secretion.

14 cl, 57 dwg, 39 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and concerns prevention of purulent-septic complications after radical mastectomy. For this purpose against the background of generally accepted complex therapy hypodermically at the level of vertebras Th II - Th VI medical mixture in composition: local anesthetic 1 ml, glucose 40% to 1 ml, 0.9% solution of sodium chloride 4 ml, glutoxim 3% 2 ml, is introduced. Procedure is carried out five times -a day before operation, on the first day after operation and then three times with 24 hour interval.

EFFECT: method ensures reduction of purulent-septic complication frequency as a result of efficient reduction of terms of lymphorrhea duration and correction of local immune-inflammatory reaction.

4 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a crystalline form of ilaprazole hydrate (2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulphinyl]-5-(1H-pyrrol-1-yl) 1H-benzimidazole). The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion, as well as a method of treating inflammatory gastrointestinal disorders.

EFFECT: novel crystalline form of ilaprazole hydrate is obtained.

7 cl, 21 dwg, 19 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to substituted sulphamide derivatives of formula I: , in which n, m, R1, R2a-c, R3, R4, R5 and R6 are as described in claim 1, in form of a racemate, enantiomers, diastereomers, mixtures of enantiomers or diastereomers or a separate enantiomer or diastereomer, bases and/or salts of physiologically compatible acids. The invention also relates to a method of producing said compounds, a medicinal agent having antagonist action on bradykinin receptor 1 (B1R), containing such compounds, use of such compounds to produce medicinal agents, as well as sulphamide-substituted derivatives selected from a group of compounds given in claim 8.

EFFECT: providing novel compounds which are suitable as pharmacologically active substances in medicinal agents for treating disorders or diseases which are at least partially transmitted through B1R receptors.

13 cl, 581 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a solid dispersion wherein revaprazan particles are surface-modified by a water-soluble polymer, a water-soluble saccharide, a surfactant or their mixture wherein the water-soluble polymer is specified in a group consisting of polyvinylpyrrolidone, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyethylene glycol, a water-soluble polyacrylic acid copolymer, polyvinyl alcohol or their mixture, and wherein the water-soluble saccharide is specified in a group consisting of lactose, white sugar, saccharose, mannitol, sorbitol, xylitol, trehalose, maltitol, dulcitol, inositol, dextrin, cyclodextrin and their mixture. The invention also refers to a method for preparing said solid dispersion. The present invention also presents a pharmaceutical composition containing the solid dispersion, and the method for producing the pharmaceutical composition.

EFFECT: invention provides improved solubility of revaprazan and reduced adhesion and agglutination properties.

16 cl, 4 dwg, 7 tbl, 55 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly gastoenterology, and concerns treating ulcerative colitis and Crohn's disease. That is ensured by the oral introduction of the probiotic Bifiform in dose 2-3 capcules. It is followed by the 4-5-fold introduction of mesenchymal stem cells in number 150-200 mil. cells in 0.5 to 1.5 ml into a mucous membrane of changed intestinal segments. Further, Bifiform is introduced in dose 1 capsule 3 times a day for 3 weeks.

EFFECT: method provides higher clinical effectiveness in said diseases.

3 ex

FIELD: medicine.

SUBSTANCE: group of invention refers to a polypeptide composition containing one or more polypeptides which are immunogenic in a vertebrate so that they induce production in the vertebrate of cells of the immune system able to recognize at least one epitope in a protein fraction of arthropod's saliva with the protein fraction of arthropod's saliva having weight of 20 kDa or less, while the polypeptides are independently specified in a polypeptide sequence SEQ ID NO:1-44 or having 7 amino acids or more partial sequences, methods for making it, using for preparing a drug.

EFFECT: group of invention is effective in treating or preventing a disease propagated by arthropods.

44 cl, 10 dwg, 21 tbl, 4 ex

Up!